Pharmaceutical Executive-06-01-2017

Pharm Exec's 17th annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.

Outlining the new leadership and C-level roles of tomorrow needed to take on the disruption event on pharma's horizon.

An honoree at HBA’s recent Women of the Year awards luncheon, Bahija Jallal’s story is one of courage and resilience.

With the patient voice growing louder in all aspects of the drug development and commercialization journey, Pharm Exec examines some of the current industry thinking on the evolving pharma-patient relationship.

A panel of biopharma executives discuss market access and the changing dynamics in reaching physicians and healthcare professionals.

There's no shortage of talent, expertise and passion in the biopharma industry. It's time for that talent to shine.

Several interventions and developments across the continent likely to keep discussions around drug affordability on high burn.

New legislation, administration priorities raise multiple challenges for new commissioner.

Although the local pharma and biotech sectors in Taiwan have yet to emulate the success story of its semiconductor industry, companies in the life sciences have reached a solid level of maturity, notably driven by the substantial investments injected by Taiwan’s successive governments over the past two decades.

Click the title above to open the Pharmaceutical Executive June 2017 issue in an interactive PDF format.